Abstracts tagged "Ankylosing spondylitis (AS) and epigenetics"

Abstract Number: 2061 • 2018 ACR/ARHP Annual Meeting
Genome-Wide DNA Methylation Analysis in Ankylosing Spondylitis
Patrick Coit¹, Prashant Kaushik², Liron Caplan³, Gail S. Kerr⁴, Jessica Walsh⁵, Maureen Dubreuil⁶, Andreas Reimold⁷ and Amr H Sawalha¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Rheumatology/Medicine, Stratton VAMC, Albany, NY, ³Div of Rheumatology, Denver VA Medical Center and University of Colorado, Aurora, CO, ⁴Rheumatology, Washington DC VAMC and Georgetown and Howard University, Washington, DC, ⁵George E. Wahlen Veteran Affairs Medical Center & University of Utah, Salt Lake City, UT, ⁶Rheumatology, VA Boston Healthcare System & Boston University School of Medicine, Boston, MA, ⁷Rheumatology, Dallas VA Medical Center and University of Texas - Southwestern, Dallas, TX
Background/Purpose: Ankylosing spondylitis is a chronic inflammatory disease characterized by inflammation of the sacroiliac joints and the spine leading to significant immobility. A subset of…
Abstract Number: 2101 • 2014 ACR/ARHP Annual Meeting
Epigenetic Study of Advanced Ankylosis in Patients with Ankylosing Spondylitis
Darren O'Reilly¹, Yuhua Zhang², Nayef Al Ghanim³, Rose Ardern³, Alexandra Munn³, Sean Hamilton³, Guangju Zhai² and Proton Rahman³, ¹Memorial University of Newfoundland, St. John's, NF, Canada, ²Discipline of Genetics, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ³Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada
Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory spinal disease characterized by ankylosis of the spine. A subset of patients develops significant ankylosis resulting in mobility…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].